Pfizer Seeks More BE Requirements for ANDAs

Pfizer is asking the FDA to add five additional bioequivalence (BE) recommendations for ANDA applicants referencing its pain drug Embeda, due to “serious concerns” that BE can be established with the four “limited studies” recommended in FDA draft guidance.
Clinical Trials Advisor